Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  OpGen, Inc.    OPGN

OPGEN, INC.

(OPGN)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

OpGen to Provide Business Update and Financial Results for the Third Quarter 2020

10/29/2020 | 06:30am EST

GAITHERSBURG, Md., Oct. 29, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its third quarter 2020 financial results after the close of the U.S. financial markets on Wednesday, November 11, 2020. OpGen’s management team will host a live conference call and audio webcast at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide an update on business activities.

Conference Call Details
 U.S. Dial-in Number: +1 (877) 705 6003
 International Dial-in Number:+1 (201) 493 6725
 Webcast:http://public.viavid.com/index.php?id=142176 
 Conference ID:13712431
   
Replay Details
 U.S. Dial-in Number:+1 (844) 512 2921
 International Dial-in Number:+1 (412) 317 6671
 Replay PIN:13712431

Following the conclusion of the conference call, a replay will be available through November 25, 2020. The live, listen-only webcast of the conference call may also be accessed by visiting the Investors section of the Company’s website at www.opgen.com. A replay of the webcast will be available following the conclusion of the call and will be archived on the Company’s website for 90 days.

About OpGen, Inc.

OpGen, Inc. (Gaithersburg, MD, USA) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with its subsidiaries, Curetis GmbH and Ares Genetics GmbH, we are developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGen’s product portfolio includes Unyvero, Acuitas® AMR Gene Panel and Acuitas® Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction.

For more information, please visit www.opgen.com.

OpGen:
Oliver Schacht
President and CEO
InvestorRelations@opgen.com

OpGen Press Contact:
Matthew Bretzius
FischTank Marketing and PR
matt@fischtankpr.com

OpGen Investor Contact:
Megan Paul
Edison Group
mpaul@edisongroup.com

Primary Logo


© GlobeNewswire 2020
All news about OPGEN, INC.
11/24OPGEN INC : Entry into a Material Definitive Agreement, Unregistered Sale of Equ..
AQ
11/24OPGEN : Announces $10 Million Private Placement Priced at the Market
AQ
11/24OpGen, Inc. Announces $10 Million Private Placement Priced at the Market
GL
11/16OPGEN : Note 2 - Liquidity and management's plans
AQ
11/13OPGEN : Corporate Presentation (PDF)
PU
11/13OPGEN INC : Entry into a Material Definitive Agreement, Other Events, Financial ..
AQ
11/12OPGEN : Ares Genetics Commercially Launches NGS-based Antibiotic Resistance Test..
AQ
11/12OpGen Group Company Ares Genetics Commercially Launches NGS-based Antibiotic ..
GL
11/12OPGEN INC : Results of Operations and Financial Condition, Financial Statements ..
AQ
11/11OPGEN : Reports Third Quarter 2020 Financial Results and Provides Business Updat..
AQ
More news
Financials (USD)
Sales 2020 4,12 M - -
Net income 2020 -24,8 M - -
Net Debt 2020 - - -
P/E ratio 2020 -1,19x
Yield 2020 -
Capitalization 45,4 M 45,4 M -
Capi. / Sales 2020 11,0x
Capi. / Sales 2021 4,06x
Nbr of Employees 39
Free-Float 99,9%
Chart OPGEN, INC.
Duration : Period :
OpGen, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OPGEN, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Average target price 5,33 $
Last Close Price 2,02 $
Spread / Highest target 180%
Spread / Average Target 164%
Spread / Lowest Target 148%
EPS Revisions
Managers
NameTitle
Oliver Schacht Chief Executive Officer & Director
Bill E. Rhodes Non-Executive Chairman
Johannes Bacher Chief Operating Officer
Timothy C. Dec CFO, Secretary & Chief Accounting Officer
Vadim Sapiro Chief Information Officer
Sector and Competitors
1st jan.Capitalization (M$)
OPGEN, INC.78.76%45
IQVIA HOLDINGS INC.9.26%32 365
HANGZHOU TIGERMED CONSULTING CO.,LTD79.46%15 070
PRA HEALTH SCIENCES, INC.-0.14%7 120
SYNEOS HEALTH, INC.12.08%6 932
NOVAVAX, INC.3,058.04%6 427